Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AHK-Cu and PEG-MGF — mechanism, side effects, legal status, and pricing.
AHK-Cu is a copper-binding tripeptide (Ala-His-Lys-Cu) structurally related to GHK-Cu, studied in dermatological research for its role in extracellular matrix remodeling and hair follicle signaling.
PEG-MGF is the pegylated form of Mechano Growth Factor (MGF), the distinct 24-amino-acid C-terminal E-peptide encoded by the IGF-1Ec splice variant (IGF-1Eb in rodents) that is transiently upregulated in muscle after mechanical loading or damage. MGF is related to but pharmacologically distinct from mature IGF-1 and IGF-1 LR3. Pegylation extends its half-life from minutes to several hours, and the compound is marketed as a research chemical for muscle repair protocols. It is not FDA-approved for any indication.
AHK-Cu
PEG-MGF
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AHK-Cu
PEG-MGF
COA corpus from Disclosed Labs — independently tested batches only.
AHK-Cu
14
COAs
99.6%
Avg purity
5
Labs
PEG-MGF
12
COAs
99.6%
Avg purity
5
Labs
Pyo et al. (Archives of Pharmacal Research, 2007) reported that AHK-Cu stimulated elongation of human hair follicles ex vivo, promoted proliferation of dermal papilla cells, and increased VEGF secretion while reducing TGF-beta1 in cultured fibroblasts. Evidence is preclinical only; no controlled clinical trials have been published.
Yang and Goldspink (FEBS Lett 2002, PMID 12095637) established that the MGF E-peptide promotes myoblast proliferation and delays terminal differentiation through a receptor distinct from IGF-1R, separating MGF pharmacology from mature IGF-1. Kandalla et al. (Mech Ageing Dev 2011, PMID 21354439) showed the 24-aa MGF E-peptide activates human muscle progenitor cells and enhances their fusion potential even from older donors. Qin et al. (Mol Cell Biochem 2012, PMID 22875667) confirmed MGF drives satellite-cell proliferation while inhibiting differentiation by down-regulating MyoD and p21. Comprehensive reviews by Matheny, Nindl & Adamo (Endocrinology 2010, PMID 20130113) and Zabłocka, Goldspink et al. (Front Endocrinol 2012, PMID 23125840) summarize the evidence across muscle, cardiac and neural tissue and caution that MGF's receptor, in vivo pharmacokinetics, and safety profile remain incompletely characterized. No randomized controlled human trials of PEG-MGF have been published. MGF and IGF-1 analogs are prohibited at all times under the WADA Code.
Key references
AHK-Cu (Cosmetic) and PEG-MGF (Performance) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs